Episodes
-
Scrip's Joseph Haas, Mandy Jackson and Kevin Grogan discuss the biopharma dealmaking environment as we reach the midpoint of 2024. Haas reviews dealmaking data from the first six months of the year and discusses what experts expect in the months ahead. Jackson and Grogan talk about the industry mood coming out of the annual BIO conference in June and what they heard at the meeting.
-
Missing episodes?
-
In Vivo Podcast Episode with Stefan Woxström by Citeline
-
Aspirin is celebrating its 125th anniversary this year. To find out what brand owner Bayer Consumer Health is doing to celebrate this occasion, and what it is doing to take the brand into the next 125 years, HBW Insight chats with the company’s senior vice president, Global Head Allergy, Cough/Cold, Pain and Heart Health, Reese Fitzpatrick, and head of R&D, North America and Therapeutics, Rachel Koontz. Already used for a variety conditions by consumers and patients across the world, the Aspirin brand has much more to offer, they argue, for example, in terms of digital self-care, with the firm working with British medtech firm Huma Therapeutics on a Heart Health Risk Assessment app that it currently markets in the US and Middle East. Aspirin also still has Rx-to-OTC switch potential, they reveal, for example in markets like Mexico where the brand is not already available without a prescription. And if that’s not enough, we also discuss Bayer’s extension of the Aspi brand into the naturals space, particularly in the cough and cold category in Europe.
Timestamps
2:25 – Introductions
3:30 – Aspirin’s 125th anniversary
5:50 – Aspirin’s brand longevity
14:15 – Challenges of self-care
25:20 – Digital self-care and chronic conditions
27:50 – Aspirin’s Rx-to-OTC switch potential
33:30 – Science and self-care
39:90 – Natural alternatives
44:15 – What’s next for Aspirin? -
Audio roundup of selected biopharma industry content from Scrip over the business week ended 28 June 2024. In this episode: global CEO remuneration; another late-stage loss for Merck KgaA; deals shift to smaller M&A, partnering; Bayer’s Parkinson’s bets bear fruit; and India looks to innovate CAR-T models.https://scrip.citeline.com/SC150517/Quick-Listen-Scrips-Five-MustKnow-ThingsPlaylist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things
-
Pink Sheet reporter and editors discuss what the FDA included in its long-awaited guidance on clinical trial diversity action plans, along with what was left out (:35), as well as an upcoming guidance on the use of artificial intelligence in regulatory decision-making (27:30).
More On These Topics From The Pink Sheet
Diversity Action Plans Should Be Brief And Waiver Requests Filed Early, US FDA Says: https://pink.citeline.com/PS154894/Diversity-Action-Plans-Should-Be-Brief-And-Waiver-Requests-Filed-Early-US-FDA-Says
Diversity Enrichment: US FDA Guidance Suggests Sponsors May Need To Overenroll Key Groups: https://pink.citeline.com/PS154895/Diversity-Enrichment-US-FDA-Guidance-Suggests-Sponsors-May-Need-To-Overenroll-Key-Groups
US FDA Guidance On Artificial Intelligence For Regulatory Decision-Making Expected This Year: https://pink.citeline.com/PS154868/US-FDA-Guidance-On-Artificial-Intelligence-For-Regulatory-Decision-Making-Expected-This-Year -
Guest speaker “Angus” Shipo Xie of Hankun Law joins Brian Yang to discuss new overseas data transfer rules, while Dexter Yan explains China biotechs' Hutchmed, Jiangsu Hengrui and Innovbent Bio’s clinical data readouts at the recent EHA and ADA annual meetings.
https://scrip.citeline.com/SC150487/China-Biotech-Podcast-EHAADA
Playlist: https://soundcloud.com/citelinesounds/sets/chinese-language-biopharma -
Audio roundup of selected biopharma industry content from Scrip over the business week ended 21 June 2024. In this episode: the outlook for 2025 launches; Merck confident in new pneumococcal vaccine; multiple US setbacks for Japanese firms; Stock Watch on Moderna missteps; and Sun’s North America head talks plans and strategy.
https://scrip.citeline.com/SC150476/Quick-Listen-Scrips-Five-MustKnow-Things
Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things -
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul
Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed
a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through
the highlights of Lung Life AI’s journey to date and its future ambition for a strategic partnership.
He also provides advice to similar diagnostic companies seeking reimbursement and
compliance with the US FDA Lab Developed Test ruling. -
In this episode, HBW Insight chats with women’s health start-up The SABI about the power of herbal medicine for hormonal wellness. “Inspired by a series of painfully honest conversations they had about their hormonal and emotional challenges,” The SABI markets a range of herbal infusions aimed at alleviating some of the impacts of painful periods and hormonal imbalances, such as digestive discomfort, sleep disruption and anxiety. The SABI founders Hilary Metcalfe and Anna Cave-Bigley also reveal the difficulties of being a woman-led, women’s health startup in a male dominated world, especially when it comes to funding and research. We also discuss the importance of getting the message right, both in terms of connecting women to their hormonal health but also distinguishing The SABI from less credible women’s wellness brands.
Timestamps:
2:00 Introductions
5:00 The power of herbs
11:45 The challenges of being a women’s health startup
17:30 The demand for natural women’s health products
24:50 Controversies surrounding natural women’s health alternatives
32:45 What’s next for The SABI
Biographies
Anna Cave-Bigley is CEO at The SABI, leading sales and strategy “with her signature drive and keen insight on everything from motherhood, hormone balance and mental health to strategy, sales and global operations.” From being a founding member of the international practice for a leading London communication consultancy to spearheading international investment initiatives for the British Government, Anna has honed her operational business expertise over 13 years. She is mother to Lorenzo and Alfie, who “inspired her to co-found The SABI after her devastating experience with clinical postpartum depression.”
Co-founder Hilary Metcalfe is a Harvard graduate and accomplished business strategist, who dedicated 12 years to impact investment, sustainability, and management consulting before her health intervened. “Conventional medicine offered only a lifetime of medication for chronic migraines and my then-undiagnosed endometriosis. Determined to find a more natural approach, I became a certified holistic nutritionist, product developer and chef, building and selling a successful plant-based food startup in Amsterdam.” During this time Hilary began formulating the remedies and products that would become The SABI’s core collection. -
Audio roundup of selected biopharma industry content from Scrip over the business week ended 14 June 2024. In this episode: Boehringer best in MASH?; biopharma funding on an upswing?; Moderna’s combo jab; clinical trial recover from pandemic; and Astellas’s US commercial head speaks.
https://scrip.citeline.com/SC150442/Quick-Listen-Scrips-Five-MustKnow-Things
Playlist: https://soundcloud.com/citelinesounds/sets/scrips-five-must-know-things -
In this podcast, Janelle Hart, Managing Editor, Citeline, joins industry experts Jessica Wall, Director of Talent Acquisition, and Morgan Seaman, Associate Director of FSS Operations, both from Advanced Clinical, to discuss the latest trends and challenges in building, scaling and differentiating workforces in the life sciences sector.
Talent acquisition is central to fostering creativity and innovation within any organization. In today’s highly competitive and fast-moving life sciences sector, it’s more important than ever. Tune into this free podcast to gain valuable insights on maintaining a competitive edge through innovative recruitment and retention strategies. Listen now to explore more! -
The oncology team from Datamonitor Healthcare and healthcare journalist, Alaric, provide broad analytical coverage of key highlights from the ASCO 2024 conference.
Apple Podcasts - https://podcasts.apple.com/us/podcast/pharma-intelligence-podcasts/id923189836
Google Podcasts - https://podcasts.google.com/feed/aHR0cHM6Ly9mZWVkcy5zb3VuZGNsb3VkLmNvbS91c2Vycy9zb3VuZGNsb3VkOnVzZXJzOjEwNjU1NDkyOC9zb3VuZHMucnNz
TuneIn - https://tunein.com/podcasts/Business--Economics-Podcasts/Pharma-Intelligence-Podcasts-p1140128/
Spotify Podcasts - https://open.spotify.com/show/3DTc3eIh4xI6pVOd6DdO67 -
Guest speaker, US-based Pink Sheet senior writer Sarah Karlin-Smith, joins Brian Yang and Dexter Yan in China to discuss the recent BIO Conference, updates to the planned US BIOSECURE Act and industry preparations for its impact. Dexter also discusses China biotech's data highlights from ASCO 2024.
https://scrip.citeline.com/SC150438/China-Biotech-Podcast-BIOSECURE-Act-Updates--ASCO-Highlights
Playlist: https://soundcloud.com/citelinesounds/sets/chinese-language-biopharma -
글로벌 제약업계는 암 연구의 미래를 어떻게 보고 있을까? Scrip의 ASCO 현장 취재 기사를 요약한 내용입니다.
https://scrip.citeline.com/SC150378/ASCO-Roundup-Looking-For-The-Future-Of-Cancer-Research
Playlist: https://soundcloud.com/citelinesounds/sets/korean-language-biopharma-mini -
Audio roundup of selected biopharma industry content from Scrip over the business week ended 7 June 2024. In this episode: BIO Notebook; ASCO roundup; data on Carvykti in community at ASCO; strong new results for tirzepatide in MASH; and orphan slowdown signals new path ahead.
https://scrip.citeline.com/SC150401/Quick-Listen-Scrips-Five-MustKnow-Things
Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things -
Generics Bulletin's editorial team discusses the latest strategic developments for major industry players Teva, Sandoz and Sawai, as well as explaining the recent debate over US patent listings in the FDA's Orange Book.
-
Guest speaker Guangzuo Luo, chief scientific officer of Bioncetech, joins China-based editors Brian Yang and Dexter Yan in this episode, which looks at Chinese biotechs going global, and the opportunities and challenges in the latest industry latest trends.
https://scrip.citeline.com/SC150370/China-Biotech-Podcast-Going-Global-Trends-Rare-Disease-Drug-Development
Playlist: https://soundcloud.com/citelinesounds/sets/chinese-language-biopharma?si=80b1209c44874afa9c44bf7d30538320&utm_source=clipboard&utm_medium=text&utm_campaign=social_sharing -
In an interview with Scrip, JB CEO Nikhil Chopra addresses rumours of a sale of a stake in the Indian pharma/CDMO company by private equity fund KKR, recent acquisitions, including from Novartis, as well as JB's ambitions to ramp up the cardiology segment and its CDMO business, which already has major clients including J&J.
https://scrip.citeline.com/SC150350/Amid-Talk-Of-KKR-Stake-Sale-JB-CEO-Stresses-Business-As-Usual -
Audio roundup of selected biopharma industry content from Scrip over the business week ended 31 May 2024. In this episode: ASCO preview; Asahi’s US acquisition; Novartis aims for renal disease dominance; paying for gene therapies; and US BIOSECURE Act diluted.
https://scrip.citeline.com/SC150361/Quick-Listen-Scrips-Five-MustKnow-Things
Playlist: https://soundcloud.com/citelinesounds/sets/scrips-five-must-know-things - Show more
